Comparing the current results to its competitors, Genfit S A reported Revenue increase in the 4 quarter 2024 by 85.82 % year on year. The revenue growth was below Genfit S A 's competitors' average revenue growth of 302.35 %, achieved in the same quarter.
Genfit S A 's Comment on Competition and Industry Peers
The company operates in a competitive environment characterized by ongoing innovations from both new and established industry participants. It faces risks associated with maintaining and protecting its intellectual property rights, as insufficient patent protection may allow competitors to develop and commercialize similar or identical products. The company depends on licensing agreements with partners, including Ipsen and Terns Pharmaceuticals, for royalty payments and commercialization activities. Competitors are developing or have authorized product candidates targeting diseases such as primary biliary cholangitis (PBC), acute-on-chronic liver failure (ACLF), and cholangiocarcinoma (CCA), as well as alternatives to liver biopsy for diagnosing metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, which present competitive challenges. Market factors influencing competitiveness include sales, marketing, reimbursement, timing of market introduction, and inclusion in treatment guidelines. The company files patent applications domestically and internationally to protect its proprietary product candidates but faces risks related to patent filing, prosecution, and enforcement. Competitors may attempt to circumvent patents by developing non-infringing technologies or seek regulatory approval to market competing products.
Akero Therapeutics Inc is a biotechnology company that focuses on the development of breakthrough treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders. Their business model revolves around advancing their proprietary drug candidates through preclinical and clinical stages to ultimately bring them to market, partnering with leading academic institutions and leveraging scientific expertise to drive innovation in the field. Akero Therapeutics aims to address the significant unmet medical needs in these areas and create value for patients, healthcare providers, and shareholders.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Galmed Pharmaceuticals Ltd's business model focuses on the development and commercialization of innovative therapeutic solutions, particularly in the field of liver and metabolic diseases.
Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics in the field of chronic liver diseases. Their business model revolves around identifying and targeting specific liver diseases with high unmet medical needs, conducting extensive research and clinical trials to develop effective therapies, and then commercializing these drugs globally to generate sustainable revenue streams. By addressing liver diseases with innovative treatments, Intercept aims to improve patient outcomes and establish a profitable position in the pharmaceutical industry.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Sources:
Genfit S a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Genfit S a versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
